Rovin BH, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:753–779. doi: 10.1016/j.kint.2021.05.015
Uffing A, et al. Recurrence of FSGS after kidney transplantation in adults. Clin J Am Soc Nephrol 2020; 15:247–256. doi: 10.2215/CJN.08970719
Bertelli R, et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003; 41:1314–1321. doi: 10.1016/S0272-6386 (03)00364-0
Gallon L, et al. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 2012; 366:1648–1649. doi: 10.1056/nejmc1202500
Watts AJB, et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 2022; 33:238–252. doi: 10.1681/ASN.2021060794
Wei C, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17:952–960. doi: 10.1038/nm.2411
Jacobs-Cachá C, et al. A misprocessed form of apolipoprotein A-I is specifically associated with recurrent focal segmental glomerulosclerosis. Sci Rep 2020; 10:1–9. doi: 10.1038/s41598-020-58197-y
D’Cunha PT, et al. Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation. Am J Transplant 2005; 5:351–355. doi: 10.1111/j.1600-6143.2004.00665.x
D’Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23:117–134. doi: 10.1053/snep.2003.50012
Alasfar S, et al. Rituximab and therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis postkidney transplantation. Transplantation 2018; 102:e115–e120. doi: 10.1097/TP.0000000000002008
Lanaret C, et al. Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. Am J Transplant 2021; 21:3021–3033. doi: 10.1111/ajt.16504
Alhamad T, et al. ACTH gel in resistant focal segmental glomerulosclerosis after kidney transplantation. Transplantation 2019; 103:202–209. doi: 10.1097/TP.0000000000002320
Jhaveri KD, et al. Treatment of recurrent focal segmental glomerular sclerosis posttransplant with a multimodal approach including high-galactose diet and oral galactose supplementation. Transplantation 2011; 91:e35–e36. doi: 10.1097/TP.0b013e3182088b67
Hattori M, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003; 42:1121–1130. doi: 10.1053/j.ajkd.2003.08.012
Yu C-C, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013; 369:2416–2423. doi: 10.1056/nejmoa1304572
Kopp JB, et al. Podocytopathies. Nat Rev Dis Primers 2020; 6:68. doi: 10.1038/s41572-020-0196-7
Hosenpud J, et al. Successful second kidney transplantation in a patient with focal glomerulosclerosis. Am J Nephrol 1985; 5:299–304. doi: 10.1159/000166952
Gohh RY, et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005; 5:2907–2912. doi: 10.1111/j.1600-6143.2005.01112.x
Hennessey B, Suter P. The voice of the patient. Home Healthc Now 2021; 33:288–289. doi: 10.1097/NHH.0000000000000239